A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab
BackgroundLecanemab is a humanized murine IgG1 antibody. Recent Phase 3 clinical trials have demonstrated its ability to reduce brain amyloid-β (Aβ) load and slow cognitive decline in patients with early Alzheimer’s disease (AD). However, since its approval, reports on adverse effects (AEs) associat...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2025-04-01
|
| Col·lecció: | Frontiers in Pharmacology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1559447/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|